Anti-osteoporotic treatments in France: initiation, persistence and switches over 6 years of follow-up
- 640 Downloads
Limited information is available on anti-osteoporotic treatment initiation patterns in France. In 2006–2013, the most frequently prescribed first-line treatment class for osteoporosis was represented by bisphosphonates (alendronic acid and risedronic acid), followed by strontium ranelate. Persistence with anti-osteoporotic treatment was low, with high proportions of treatment discontinuations and switches.
This epidemiological, longitudinal study described first-line treatment initiation, persistence, switches to second-line treatment, and medical care consumption in osteoporotic patients in France during the 2007–2013 period.
Patients aged ≥50 years, who were recorded in a French claims database and did not die during the observation period, were included if they met ≥1 inclusion criteria for osteoporosis in 2007 (≥1 reimbursement for anti-osteoporotic treatment, hospitalisation for osteoporotic fracture (spine, hip, femur, forearm bones, humerus, wrist), or ≥1 reimbursement for long-term osteoporosis-associated status). We collected data on consumption of anti-osteoporotic treatment (alendronic acid, ibandronic acid, risedronic acid, zoledronic acid, raloxifene, strontium ranelate, teriparatide) and of osteoporosis-related medical care after the date of first reimbursement for anti-osteoporotic treatment.
We obtained 2219 patients with a 6-year follow-up and 1387 who initiated an anti-osteoporotic treatment in 2007 and who can be selected for the treatment regimen analysis. The most frequently used first-line treatments were alendronic acid (32.7 %), risedronic acid (22.4 %), strontium ranelate (19.3 %), ibandronic acid (13.1 %) and raloxifene (12.2 %). Among patients who received these treatments, the highest persistence after 6 years was observed for raloxifene (37.3 %), alendronic acid (35.1 %) and risedronic acid (32.3 %). Treatment discontinuations were reported for 35.5 % (raloxifene) to 53.4 % (strontium ranelate) and treatment switches for 27.4 % (alendronic acid) to 56.6 % (ibandronic acid) of these patients.
This study showed that persistence with anti-osteoporotic treatment was relatively low in France, with high proportions of treatment discontinuations and switches, and that patients with osteoporosis were insufficiently monitored by bone specialists.
KeywordsFirst-line treatment France Medical care Osteoporosis Persistence Switch
We thank the French National Health Service (Caisse Nationale de l’Assurance Maladie des Travailleurs Salariés) and the Institute of Health Data (Institut des Données de Santé) for providing data. The authors thank Claire Verbelen (XPE Pharma and Science, Wavre, Belgium) for professional medical writing support. This study was funded by MSD France.
Compliance with ethical standards
Conflicts of interest
MB was a PhD student and part-time employee of MSD France at the time of the study. CBC received honorarium from Amgen, Lilly, MSD. BC received honorarium from Amgen, Ferring, Lilly, Medtronic, MSD, Roche diagnostics. LL is a full-time employee of MSD France. MG has nothing to declare. EVG has nothing to declare.
- 3.Briot K, Cortet B, Thomas T, Audran M, Blain H, Breuil V, Chapuis L, Chapurlat R, Fardellone P, Feron JM, Gauvain JB, Guggenbuhl P, Kolta S, Lespessailles E, Letombe B, Marcelli C, Orcel P, Seret P, Tremollieres F, Roux C (2012) 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis. Joint Bone Spine 79:304–313. doi: 10.1016/j.jbspin.2012.02.014 CrossRefPubMedGoogle Scholar
- 6.Kanis JA on behalf of the World Health Organisation Scientific Group (2007). Assessment of osteoporosis at the primary health care level. Technical Report. World Health Organisation Collaborating Center for Metabolic Bone diseases, University of Sheffield, UK. Printed by the University of Sheffield. http://www.shef.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf. Accessed 8 April 2016.
- 7.Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, Berger ML, Santora AC, Sherwood LM (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 286:2815–2822CrossRefPubMedGoogle Scholar
- 9.Agence Française de Sécurité Sanitaire des Produits de Santé (2006). Traitement medicamenteux de l’ostéoporose post-ménopausique—recommandations—actualisation 2006. http://www.grio.org/documents/rcd-4-1263309820.pdf. Accessed 8 April 2016.
- 12.Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY, Scientific Advisory Board of the European Society for C, Economic Aspects of O, Osteoarthritis, the Committee of Scientific Advisors of the International Osteoporosis F (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23–57. doi: 10.1007/s00198-012-2074-y CrossRefPubMedGoogle Scholar
- 16.Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwinski E, Krieg MA, Mellstrom D, Radominski SC, Reginster JY, Resch H, Ivorra JA, Roux C, Vittinghoff E, Daizadeh NS, Wang A, Bradley MN, Franchimont N, Geller ML, Wagman RB, Cummings SR, Papapoulos S (2013) The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab 98:4483–4492. doi: 10.1210/jc.2013-1597 CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Caisse nationale de l’Assurance Maladie des travailleurs salariés (2015). Améliorer la qualité du système de santé et maîtriser les dépenses. Propositions de l’Assurance Maladie pour 2016. http://www.ameli.fr/rapport-charges-et-produits-2016/#/0. Accessed 20 May 2016.
- 20.De Roquefeuil L, Studer A, Neumann A, Merlière Y (2009) The Echantillon généraliste de bénéficiaires: representativeness, scope and limits. Prat Organ. Soins 40:213–223Google Scholar
- 21.Direction de la stratégie des études et des statistiques de la Caisse Nationale d’Assurance Maladie des Travailleurs Salariés (CNAMTS). Generalist Sample of Beneficiaries (EGB)—SNIIR-AM (National Health Insurance Cross-Schemes Information System). https://epidemiologie-france.aviesan.fr/en/epidemiology/records/echantillon-generaliste-de-beneficiaires-sniir-am. Accessed 8 April 2016.
- 22.Haute Autorité de la Santé. Transparency Committee Opinion. 19 December 2007. ACLASTA: inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the extension of indication: “Treatment of osteoporosis in postmenopausal women at high risk of fracture.” Available from: http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-11/aclasta_ct_5082.pdf. Accessed on 6 May 2016.
- 26.Cotte FE, Mercier F, De Pouvourville G (2008b) Relationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysis. Clin Ther 30:2410–2422. doi: 10.1016/j.clinthera.2008.12.019 CrossRefPubMedGoogle Scholar
- 27.Cotte FE, Cortet B, Lafuma A, Avouac B, Hasnaoui AE, Fardellone P, Pouchain D, Roux C, Gaudin AF (2008a) A model of the public health impact of improved treatment persistence in post-menopausal osteoporosis in France. Joint Bone Spine 75:201–208. doi: 10.1016/j.jbspin.2007.06.004 CrossRefPubMedGoogle Scholar
- 29.Yun H, Curtis JR, Guo L, Kilgore M, Muntner P, Saag K, Matthews R, Morrisey M, Wright NC, Becker DJ, Delzell E (2014) Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiaries. BMC Musculoskelet Disord 15:112. doi: 10.1186/1471-2474-15-112 CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Halpern R, Becker L, Iqbal SU, Kazis LE, Macarios D, Badamgarav E (2011) The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis. J Manag Care Pharm 17:25–39PubMedGoogle Scholar
- 33.Karlsson L, Lundkvist J, Psachoulia E, Intorcia M, Ström O (2015) Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis. Osteoporos Int 26(10):2401–2411. doi: 10.1007/s00198-015-3253-4 CrossRefPubMedPubMedCentralGoogle Scholar
- 37.Erny F, Auvinet A, Chu Miow Lin D, Pioger A, Haguenoer K, Tauveron P, Jacquot F, Rusch E, Goupille P, Mulleman D (2015) Management of osteoporosis in women after forearm fracture: data from a French health insurance database. Joint Bone Spine 82:52–55. doi: 10.1016/j.jbspin.2014.07.007 CrossRefPubMedGoogle Scholar
- 38.Haute Autorité de Santé (2011). PROLIA: Inscription Sécurité Sociale et Collectivités http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-03/prolia_14122011_avis_ct10890.pdf. Accessed 8 April 2016.
- 39.Gosselin J, Bougnères C, Bennet P, Avenel G, Vittecoq O, Daragon A (2016) Impact des nouvelles recommandations du traitement médicamenteux de l’ostéoporose post-ménopausique. Étude rétrospective des patientes vues en consultation « ostéoporose » entre 2006 et 2012. Rev Rhum. doi: 10.1016/j.rhum.2015.01.001 CrossRefGoogle Scholar